| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Beone Medicines Ltd. (ONC) has 8 insiders with recent SEC Form 4 filings, including 0 buys and 64 sells. ONC is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 4.58M | $1.24B | - | |
| Pres | 1.45M | $392.10M | - | |
| VP | 97.0K | $26.21M | - | |
| CEO | 3.3K | $882.9K | - | |
| Dir | 2.6K | $709.7K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 20, 2025 | Wu Xiaobin54 | President, COO &Gm China | Sale+OE | 51,921 | $240.46 | $12,485,044.71 | -78.5% | -3.2% | +48.3% | |
| Feb 4, 2025 | Wang Xiaodong58 | Director, Chair, Scientific Advisory Brd | Sale+OE | 41,760 | $225.69 | $9,424,955.38 | -28.4% | +14.0% | +57.9% | |
| Jan 7, 2025 | Wang Xiaodong58 | Director, Chair, Scientific Advisory Brd | Sale+OE | 41,760 | $176.50 | $7,370,514.66 | -49.9% | +26.0% | +90.7% | |
| Dec 10, 2024 | Wang Xiaodong58 | Director, Chair, Scientific Advisory Brd | Sale+OE | 41,760 | $186.90 | $7,805,105.81 | -25.0% | +29.4% | +72.1% | |
| Dec 9, 2024 | Baker Bros. Advisors LP59 | Director | Sell | 1,037,017 | $187.27 | $194,200,043.13 | -4.9% | +16.9% | +53.5% | |
| Dec 6, 2024 | Wu Xiaobin54 | President, COO &Gm China | Sell | 0 | $0.00 | - | New | +25.0% | +57.0% | |
| Dec 2, 2024 | Hhlr Advisors, Ltd.60 | 10% Owner | Sell | 17,842,500 | $200.00 | $3,568,500,000.00 | -12.5% | +19.3% | +60.5% | |
| Nov 26, 2024 | Wang Xiaodong58 | Director, Chair, Scientific Advisory Brd | Sale+OE | 48,351 | $190.08 | $9,190,569.92 | -15.6% | +34.6% | +77.3% | |
| Oct 8, 2024 | Oyler John59 | Chief Executive Officer | Sell | 16,175 | $232.22 | $3,756,092.18 | -28.1% | -23.3% | +49.1% | |
| Sep 30, 2024 | Lee Chan Henry47 | SVP, General Counsel | Sell | 1,202 | $237.10 | $284,994.20 | -100% | -18.1% | +51.8% |